Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair.
The European Commission has levied a substantial penalty on DNA sequencing giant Illumina for closing its takeover of cancer detection company Grail without EU regulatory
Researchers in the UK say Grail’s blood test for more than 50 different types of cancer has shown promise in a trial involving thousands of people with suspected cancer sy
The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an
Dr Prasanth Reddy, head of oncology at Labcorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testi
The EU has blocked the merger of Illumina and Grail, saying the deal would stifle innovation in blood-based diagnostics for cancer diagnostics, just days after a bid by the US authorities t
Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.